Atopic dermatitis (AD) is characterized by a complex pathophysiology with a wide spectrum of phenotypes. This high diversity makes mechanistic in silico approaches particularly adapted for guiding clinical development.
In the context of the bacterial lysate OM-85’s development to treat atopic dermatitis,  OM Pharma wanted to conduct an in silico exploration of the immune mechanisms driving the treatment response in order to characterize the best responders.
Nova has built a mechanistic model of AD representing the interplay between the skin barrier and the immune system in a pediatric population.
Download case study
Get your questions answered by downloading the free pdf and learn more about our study!